Galapagos NV Cash Flow Conversion Efficiency
Galapagos NV cash flow conversion efficiency. Based on the latest financial reports, Galapagos NV (GXEA) has a cash flow conversion efficiency ratio of -0.025x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-82.75 Million ≈ $-96.74 Million USD) by net assets (€3.25 Billion ≈ $3.80 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Galapagos NV (2016–2025)
Cash flow conversion efficiency of Galapagos NV from 2016 to 2025. This chart illustrates how Galapagos NV's cash flow conversion efficiency has evolved over time, based on yearly financial data. View GXEA share price today for real-time trading data and today's change.
Galapagos NV Cash Flow Conversion Ratio Explained
Galapagos NV cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Galapagos NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Galapagos NV ranked by their cash flow conversion efficiency. Also see Galapagos NV (GXEA) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Systex Corp
TW:6214
|
0.254x |
|
Akzo Nobel India Limited
NSE:AKZOINDIA
|
-0.079x |
|
Skywater Technology Inc
NASDAQ:SKYT
|
-0.077x |
|
Xenia Hotels & Resorts Inc
NYSE:XHR
|
0.052x |
|
Chambal Fertilizers & Chemicals Limited
NSE:CHAMBLFERT
|
0.033x |
|
Trinity Capital Inc.
NASDAQ:TRIN
|
-0.205x |
|
Stanmore Resources Ltd
AU:SMR
|
0.133x |
|
Bayer Cropscience Limited
NSE:BAYERCROP
|
-0.012x |
Annual Cash Flow Conversion Efficiency for Galapagos NV (2016–2025)
The table below shows the annual cash flow conversion efficiency of Galapagos NV from 2016 to 2025. Review Galapagos NV (GXEA) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €3.24 Billion ≈ $3.78 Billion |
€-257.46 Million ≈ $-300.99 Million |
-0.080x | +27.98% |
| 2024-12-31 | €2.90 Billion ≈ $3.39 Billion |
€-320.03 Million ≈ $-374.14 Million |
-0.110x | +40.49% |
| 2023-12-31 | €2.80 Billion ≈ $3.27 Billion |
€-518.97 Million ≈ $-606.73 Million |
-0.186x | +6.32% |
| 2022-12-31 | €2.53 Billion ≈ $2.95 Billion |
€-500.54 Million ≈ $-585.19 Million |
-0.198x | -3.96% |
| 2021-12-31 | €2.64 Billion ≈ $3.09 Billion |
€-503.83 Million ≈ $-589.03 Million |
-0.191x | -19.10% |
| 2020-12-31 | €2.67 Billion ≈ $3.12 Billion |
€-427.34 Million ≈ $-499.60 Million |
-0.160x | -114.34% |
| 2019-12-31 | €2.88 Billion ≈ $3.36 Billion |
€3.21 Billion ≈ $3.75 Billion |
1.116x | +1050.99% |
| 2018-12-31 | €1.21 Billion ≈ $1.42 Billion |
€-142.47 Million ≈ $-166.56 Million |
-0.117x | +19.24% |
| 2017-12-31 | €1.01 Billion ≈ $1.18 Billion |
€-147.03 Million ≈ $-171.89 Million |
-0.145x | -146.04% |
| 2016-12-31 | €758.70 Million ≈ $887.00 Million |
€239.40 Million ≈ $279.89 Million |
0.316x | -- |
About Galapagos NV
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in… Read more